Brock University Lung Nodule Malignancy Model
Estimates probability of malignancy in incidental pulmonary nodules detected on CT. Based on the Pan-Canadian Early Detection of Lung Cancer Study. Guides surveillance and biopsy decisions.
Score interpretation
→ Brock Low Risk: <5% probability of malignancy. Follow Fleischner Society or BTS guidelines — annual low-dose CT surveillance for 2 years if nodule ≥6 mm. No biopsy required.
→ Brock Intermediate Risk: 5–20% malignancy probability. 3-monthly CT surveillance; consider PET/CT if nodule ≥8 mm. Multi-disciplinary team (MDT) discussion. Reassess at each interval.
→ Brock High Risk: >20% malignancy probability. Urgent MDT review; PET/CT; biopsy (CT-guided or bronchoscopic) or surgical resection. Refer to thoracic oncology.
Interpretation bands for the Brock Lung Model. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Fong Clinical Risk Score for Colorectal Cancer Recurrence · Oncology
- CRASH Score for Chemotherapy Risk Assessment in Elderly Patients · Oncology
- Ann Arbor Staging System for Lymphoma · Oncology
- Rai Staging System for CLL · Oncology
- Follicular Lymphoma International Prognostic Index (FLIPI) · Oncology
- International Staging System for Multiple Myeloma (ISS) · Oncology
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.